Sunshine Biopharma Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Sunshine Biopharma Inc. (SBFM) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.92% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-04-03
- Sunshine Biopharma Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.92%.
- Sunshine Biopharma Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -1.04%.
- Sunshine Biopharma Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -1.38%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.92% 10-K · filed 2026-04-03 | |
| 2024-12-31 | -1.04% 10-K · filed 2026-04-03 | -1.05% 10-K · filed 2025-04-01 |
| 2023-12-31 | -1.38% 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |